OB

Onyx Biotec Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Onyx Biotec Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Onyx Biotec Ltd Q2 FY27 key numbers

Revenue
Revenue from operations for the quarter ended September 30, 2026: ₹4,340.86 Lakhs.

As stated in Onyx Biotec Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.

Based on Onyx Biotec Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹39
Market cap₹71 Cr

The short version

Revenue from operations for the quarter ended September 30, 2026: ₹4,340.86 Lakhs. EBITDA for the quarter ended Sep 30, 2026: ₹270.59 lakhs (Calculated as Profit before exceptional items and tax ₹125.83 lakhs + Depreciation ₹144.54 lakhs).

From Onyx Biotec Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.

How did Onyx Biotec's revenue grow in the September 2026 quarter?

  • Revenue from operations for the quarter ended September 30, 2026: ₹4,340.86 Lakhs
  • Revenue from operations for the same quarter previous year (September 30, 2025): ₹3,458.50 Lakhs
  • Year-on-year revenue growth: ₹4,340.86 Lakhs vs ₹3,458.50 Lakhs, an increase of approximately 25.47%

2 more points from Onyx Biotec Ltd's call on revenue

Create a free account to keep reading this call

What happened to Onyx Biotec's margins in Q2 FY27?

See what Onyx Biotec Ltd said on profitability & margins — free account, 30 seconds.

What capex is Onyx Biotec planning?

  • Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use
  • Allocation: INR 607.70 Lakhs (original), Fund utilized: INR 573.30 Lakhs
  • Status: Nil deviation, advance of INR 22.07 Lakhs paid as of September 30, 2026; bills to be received post-completion
  • Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections
  • Allocation: INR 124.05 Lakhs (original), Fund utilized: INR 91.55 Lakhs
  • Work in progress

2 more points from Onyx Biotec Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Onyx Biotec raising money or cutting debt?

See what Onyx Biotec Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Onyx Biotec's order book?

See what Onyx Biotec Ltd said on order book & pipeline — free account, 30 seconds.

More Q2 FY27 results in Pharmaceuticals & Biotechnology

All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Onyx Biotec Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Onyx Biotec Ltd Q2 FY27 results?

Revenue from operations for the quarter ended September 30, 2026: ₹4,340.86 Lakhs. EBITDA for the quarter ended Sep 30, 2026: ₹270.59 lakhs (Calculated as Profit before exceptional items and tax ₹125.83 lakhs + Depreciation ₹144.54 lakhs).

What is Onyx Biotec Ltd share price analysis?

Onyx Biotec Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹71 Cr. Investors should review the full earnings analysis for detailed insights.

Is Onyx Biotec Ltd planning capital expenditure?

Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use.

Keep Onyx Biotec Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.